Laboratory

Setting A New Security Benchmark: Kudelski IoT's Semiconductor Alliances Redefine IoT Provisioning

Retrieved on: 
Wednesday, April 10, 2024
Control, Silicon Labs, Consumer electronics, Medical device, Connectivity Standards Alliance, Original equipment manufacturer, Internet of things, Library, Embedded, FOTA, Laboratory, Senior, Kudelski Group, Kudelski, Silicon, OEM, Home automation, Cloud computing, STMicroelectronics, Automation, PKI, Integrated circuit, Video game

Setting A New Security Benchmark: Kudelski IoT's Semiconductor Alliances Redefine IoT Provisioning

Key Points: 
  • Setting A New Security Benchmark: Kudelski IoT's Semiconductor Alliances Redefine IoT Provisioning
    Premier integration with Microchip, and collaborative partnerships with ST Microelectronics, Infineon, and Silicon Labs radically simplify a critical IoT security requirement.
  • Kudelski IoT libraries are integrated with semiconductor partner tools to enable device manufacturers to personalize their products in the factory or in the field.
  • Hardy Schmidbauer, Senior Vice President at Kudelski IoT, said, “For many IoT device manufacturers, security provisioning is today a laborious manual process that is prone to error, seriously compromising the security of individual devices, or even of a manufacturer’s whole chain of security.
  • By partnering with top IC manufacturers, Kudelski IoT is making provisioning a simpler, more automated, and secure process than ever before.

EQS-News: Medios acquires Dutch market leader in pharmaceutical compounding services

Retrieved on: 
Wednesday, April 10, 2024
Tax, Consolidated, Growth, Frankfurt Stock Exchange, XETRA, FY, Patient, Pharmacy, Hospital, Acquisition, Laboratory, GMP, API, Depreciation, Fine chemical

Ceban is the Dutch market leader in compounding and has growing market positions in Belgium and Spain.

Key Points: 
  • Ceban is the Dutch market leader in compounding and has growing market positions in Belgium and Spain.
  • The purchase price for 100% of Ceban shares includes a cash component of €235.3 million and 1.7 million Medios shares.
  • The acquisition of Ceban gives Medios an outstanding position in the Dutch pharmaceutical market.
  • Ceban has a market leading position in pharmaceutical compounding in the Netherlands, a top-3 position in Belgium and a top-5 position in Spain.

NJIT Aims to Be an Innovation Nexus Under Its New Strategic Plan

Retrieved on: 
Tuesday, April 9, 2024
Nexus, Success, Faculty, Government, Innovation, Learning, Growth, Acceleration, Converge, COVID-19, NJIT, Artificial intelligence, AI, Social responsibility, Translation, Laboratory, Student, Digital transformation, Investment, Creativity, Ecosystem, Management

The plan, NJIT Makes An Innovation Nexus, identifies six priorities, spells out the university’s mission to be a leader in research, innovation and entrepreneurship, and reaffirms its core values, including collaboration, social responsibility, diversity and sustainability.

Key Points: 
  • The plan, NJIT Makes An Innovation Nexus, identifies six priorities, spells out the university’s mission to be a leader in research, innovation and entrepreneurship, and reaffirms its core values, including collaboration, social responsibility, diversity and sustainability.
  • At the same time, NJIT will focus on creating a holistic campus environment and helping graduates realize their career goals.
  • “Innovation is at the core of what we do,” NJIT President Teik C. Lim said.
  • Another key player here is the New Jersey Innovation Institute, an NJIT corporation that turns great ideas into new businesses.

Wyss Institute’s AminoX project receives funding from Northpond Labs to accelerate innovation in protein-based therapeutics

Retrieved on: 
Monday, April 8, 2024
Molecule, Research, Innovation, Patient, DNA, Wyss Institute, Engineering, Protein, Laboratory, Organic acid, Harvard University, CRISPR, Drug development, Wyss, Biological engineering, Therapy, Genetic code, FDA, Antiandrogen, Vocabulary, Fine chemical

This is the fourth Wyss project selected by Northpond Labs for additional funding.

Key Points: 
  • This is the fourth Wyss project selected by Northpond Labs for additional funding.
  • The Laboratory has previously funded the Wyss’ eRNA (now being commercialized by EnPlusOne Biosciences ), SomaCode , and Lab-on-a-Molecule projects.
  • “The AminoX platform has the potential to transform our ability to develop differentiated protein-based therapeutics by significantly expanding the vocabulary of building blocks that can be incorporated into biologics at high throughput.
  • We are thrilled that the AminoX team’s journey to the market will be accelerated by this support,” said Angelika Fretzen, Ph.D., M.B.A., the Wyss Institute’s Technology Translation Director & Chief Operating Officer.

Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing

Retrieved on: 
Friday, April 5, 2024
CDX, Nucleic acid thermodynamics, Tissue, NGS, DNA, RUO, Laboratory, Urine, BDD, Cancer, Liquid biopsy, Deletion, Blood, FDA, Food

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit. This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, facilitating global applications in clinical trials, companion diagnostics (CDx) development, and patient testing.

Key Points: 
  • HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.
  • This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, facilitating global applications in clinical trials, companion diagnostics (CDx) development, and patient testing.
  • This newly introduced PredicineCARE™ NGS kit integrates a comprehensive, state-of-the-art NGS assay capable of detecting point mutations, indels, fusions, amplifications, and deletions in key cancer-associated genes.
  • “Predicine’s centralized global lab network coupled with the decentralized kitted offering provides a standardized approach to support clinical trials, CDx development and patient testing on a global scale.”

Koryx Copper Intersects 168.60 Metres at 0.40% Cu Eq Including Multiple 2 m Intersections >1.00% Cu Eq and 34.00 m at 0.73% Cu Eq Including 2 m at 2.28% Cu Eq

Retrieved on: 
Thursday, April 4, 2024
Element, Quality control, Molybdenum, National Instrument 43-101, Mineral Resources Limited, ALS, ICP, Copper, Bachelor of Science, Gold, News, Laboratory, Geology, National instrument, Qualified person (European Union), Honours degree, Planview, Road

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Koryx Copper Inc. ("Koryx" or “the Company") (TSX-V: KRY) announces the third assay results from its current drilling program at its Haib Copper project in southern Namibia.  The Company’s latest four drill holes continue to confirm that the deposit can deliver high grades over substantial widths within the known historical resource.

Key Points: 
  • CuEq (copper equivalent) has been used to express the combined value of copper and molybdenum and is provided for illustrative purposes only.
  • Also half-way up the southern slope it too was positioned to close the sample spacing in this part of Pit1.
  • HM39 was drilled west of and parallel to HM34 and was positioned to close the sample spacing in this direction.
  • Over time, it has seen several transformations including shearing and faulting events that appear to have further concentrated Cu and Mo.

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, April 2, 2024
ODD, Research, Growth, Drug discovery, Exercise, NRX, CFO, RNA, Laboratory, Contract research organization, Regenerative medicine, Investigational New Drug, Safety, Spinal cord injury, Intellectual property, Plasma protein binding, Small RNA, FDA, Food, Cryptocurrency

TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.

Key Points: 
  • TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.
  • For the fourth quarter of 2023, expenses were US$0.31 million, compared to US$0.39 million in the previous year.
  • For the fourth quarter of 2023, expenses were US$0.40 million, compared to US$0.46 million in the previous year.
  • For the fourth quarter of 2023, expenses were US$0.02 million, compared to US$0.17 million in the previous year.

Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023

Retrieved on: 
Wednesday, March 27, 2024
Financial statement, Growth, Infertility, International, IVF, Travel, EDT, Acquisition, Laboratory, Consumables, Adjustment, Investment, Depreciation, Analysis, Marketing, Hand, Bookkeeping

Results of Operations for the Year ended December 31, 2023

Key Points: 
  • Results of Operations for the Year ended December 31, 2023
    Hamilton Thorne sales increased 16% to $67,225,476 for the year-ended December 31, 2023, an increase of $9,047,409 from $58,178,067 during the previous year.
  • Consumable sales in 2023 outpaced the Company’s overall growth despite being affected by the recall of certain products by one of the Company’s contract manufacturers.
  • We are expecting first quarter 2024 reported revenues of between $19.0 to 19.4M, with organic growth for the quarter of approximately 8%.
  • Financial Statements and accompanying Management Discussion and Analysis for the periods are available on www.sedar.com and the Hamilton Thorne website.

Thermo Fisher Scientific Innovations at Analytica 2024 Optimize Workflows and Enable Precise Analysis Across Life Sciences, Applied and Industrial Markets

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Chemicals, Plastics, Health, Manufacturing, Other Education, Professional Services, Environment, Research, Education, Data Analytics, Hardware, Science, Green Technology, Environmental monitoring, Instrument, Quality control, QA/QC, Conference, Environmental chamber, Pharmacy, LIMS, Thermo Fisher Scientific, Laboratory, Investment, CFR, ULT, Data management, XRD

Analytica 2024 - Thermo Fisher Scientific, Inc. is debuting its recently launched innovative products, hosting educational presentations and showcasing live lab demos for customers working in laboratory technology, analysis, biotechnology, and environmental quality during the 2024 Analytica Conference.

Key Points: 
  • Analytica 2024 - Thermo Fisher Scientific, Inc. is debuting its recently launched innovative products, hosting educational presentations and showcasing live lab demos for customers working in laboratory technology, analysis, biotechnology, and environmental quality during the 2024 Analytica Conference.
  • “Advancements in data analytics and optimized laboratory workflows that enable fast, precise analysis are key to propelling the field of analytical science forward,” said Dan Shine, senior vice president and president, Analytical Instruments, Thermo Fisher.
  • Real-time monitoring with process analytical technology - The Thermo Scientific™ MarqMetrix™ All-In-One Process Raman Analyzer enables real-time, accurate spectral results for in-line, at-line, or on-line process monitoring.
  • For more information regarding Thermo Fisher products and services exhibited at Analytica 2024, please visit the website or booth 101 in hall B1.

Thermo Fisher Scientific Launches New ENERGY STAR certified TSX Universal Series ULT Freezers to Deliver Tighter Temperature Control and Faster Recovery Times

Retrieved on: 
Monday, April 8, 2024
Other Health, Research, Pharmaceutical, Sustainability, Medical Devices, Environment, Health Technology, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, ACT, Temperature, Thermo Fisher Scientific, Laboratory, GMP, TSX, ULT, Multimedia, ISO, Medical device

Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers.

Key Points: 
  • Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers.
  • With enhancements to performance, user experience and energy efficiency, the Thermo Scientific™ TSX™ Universal Series ULT Freezers seamlessly adapt to scientists’ workflows across a variety of lab settings, marking a new era in performance, reliability, and sustainability.
  • With Universal V-Drive technology, tighter control, faster recovery times, universal voltage, and an expanded setpoint range, the TSX Universal Series seamlessly adapts to diverse workflows, from high-use academic labs to longer-term storage facilities.
  • Delivering both industry leading performance and energy efficiency, the TSX Universal Series allows labs to meet their sustainability goals without sacrificing performance.